The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 172-182

  Willison, Hugh J ^a   Halstead, Susan K ^a   Beveridge, Erin ^a   Zitman, Femke M P ^b   Greenshields, Kay N ^a   Morgan, B Paul ^c   Plomp, Jaap J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antibody; Complement; Ganglioside; Guillain Barr syndrome; Miller Fisher syndrome; Motor nerve terminal

Indexed keywords

APT 070; COMPLEMENT; COMPLEMENT INHIBITOR; ECULIZUMAB; EV 576; GANGLIOSIDE ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEMENT ACTIVATION; DIAPHRAGM PARALYSIS; DRUG MECHANISM; ELECTROPHYSIOLOGY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; MINIATURE ENDPLATE POTENTIAL; MYASTHENIA GRAVIS; NERVE ENDING; NERVE INJURY; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANTIBODIES; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; MICE; MODELS, BIOLOGICAL; NEUROMUSCULAR JUNCTION; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 51649106358     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.028     Document Type: Article

References (55)

1. Benatar M.G., Willison H.J., and Vincent A. Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. J. Neuroimmunol. 80 (1997) 1-5
2. Buchwald B., Bufler J., Carpo M., Heidenreich F., Pitz R., Dudel J., Nobile-Orazio E., and Toyka K.V. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56 (2001) 67-74
3. Bullens R.W., O'Hanlon G.M., Wagner E., Molenaar P.C., Furukawa K., Furukawa K., Plomp J.J., and Willison H.J. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J. Neurosci. 22 (2002) 6876-6884
4. Chiba A., Kusunoki S., Shimizu T., and Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31 (1992) 677-679
5. Donev R.M., Sivasankar B., Mizuno M., and Morgan B.P. The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility. Mol. Immunol. 45 (2008) 534-542
6. Ebanks R.O., and Isenman D.E. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol. Immunol. 33 (1996) 297-309
7. Fearon D.T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 1971-1975
8. Fearon D.T., and Austen K.F. Current concepts in immunology: the alternative pathway of complement-a system for host resistance to microbial infection. N. Engl. J. Med. 303 (1980) 259-263
9. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., and Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28 (2000) 41-51
10. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med. 255 (1956) 57-65
11. Goodfellow J.A., Bowes T., Sheikh K., Odaka M., Halstead S.K., Humphreys P.D., Wagner E.R., Yuki N., Furukawa K., Furukawa K., Plomp J.J., and Willison H.J. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 25 (2005) 1620-1628
12. Goodyear C.S., O'Hanlon G.M., Plomp J.J., Wagner E.R., Morrison I., Veitch J., Cochrane L., Bullens R.W., Molenaar P.C., Conner J., and Willison H.J. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104 (1999) 697-708
13. Hafer-Macko C.E., Sheikh K.A., Li C.Y., Ho T.W., Cornblath D.R., McKhann G.M., Asbury A.K., and Griffin J.W. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39 (1996) 625-635
14. Halstead S.K., O'Hanlon G.M., Humphreys P.D., Morrison D.B., Morgan B.P., Todd A.J., Plomp J.J., and Willison H.J. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127 (2004) 2109-2123
15. Halstead S.K., Humphreys P.D., Goodfellow J.A., Wagner E.R., Smith R.A., and Willison H.J. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 58 (2005) 203-210
16. Halstead S.K., Morrison I., O'Hanlon G.M., Humphreys P.D., Goodfellow J.A., Plomp J.J., and Willison H.J. Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia 52 (2005) 177-189
17. Halstead S.K., Zitman F.M., Humphreys P.D., Greenshields K., Verschuuren J.J., Jacobs B.C., Rother R.P., Plomp J.J., and Willison H.J. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131 (2008) 1197-1208
18. Halstead, S.K., Humphreys, P.D., Zitman, F.M.P., Hamer, J., Plomp, J.J., Willison, H.J., in press. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J. Periph. Nervous System.
19. Hepburn N.J., Williams A.S., Nunn M.A., Chamberlain-Banoub J.C., Hamer J., Morgan B.P., and Harris C.L. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J. Biol. Chem. 282 (2007) 8292-8299
20. Ho T.W., Hsieh S.T., Nachamkin I., Willison H.J., Sheikh K., Kiehlbauch J., Flanigan K., McArthur J.C., Cornblath D.R., McKhann G.M., and Griffin J.W. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 48 (1997) 717-724
21. Kuwabara S., Bostock H., Ogawara K., Sung J.Y., Kanai K., Mori M., Hattori T., and Burke D. The refractory period of transmission is impaired in axonal Guillain-Barre syndrome. Muscle Nerve 28 (2003) 683-689
22. Hughes R.A., and Cornblath D.R. Guillain-Barre syndrome. Lancet 366 (2005) 1653-1666
23. Kazatchkine M.D., Fearon D.T., and Austen K.F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J. Immunol. 122 (1979) 75-81
24. Kieseier B.C., and Hartung H.P. Therapeutic strategies in the Guillain-Barre syndrome. Semin. Neurol. 23 (2003) 159-168
25. Lange D.J., Deangelis T., and Sivak M.A. Single-fiber electromyography shows terminal axon dysfunction in Miller Fisher syndrome: a case report. Muscle Nerve 34 (2006) 232-234
26. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., and Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110 (2002) 1269-1274
27. Lo Y.L., Leoh T.H., Dan Y.F., Lim L.L., Seah A., Fook-Chong S., and Ratnagopal P. Presynaptic neuromuscular transmission defect in the Miller Fisher syndrome. Neurology 66 (2006) 148-149
28. Lu J.L., Sheikh K.A., Wu H.S., Zhang J., Jiang Z.F., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W., and Ho T.W. Physiologic-pathologic correlation in Guillain-Barre syndrome in children. Neurology 54 (2000) 33-39
29. Morgan B.P., Berg C.W., and Harris C.L. "Homologous restriction" in complement lysis: roles of membrane complement regulators. Xenotransplantation 12 (2005) 258-265
30. Morgan B.P., Chamberlain-Banoub J., Neal J.W., Song W., Mizuno M., and Harris C.L. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin. Exp. Immunol. 146 (2006) 294-302
31. O'Hanlon G.M., Plomp J.J., Chakrabarti M., Morrison I., Wagner E.R., Goodyear C.S., Yin X., Trapp B.D., Conner J., Molenaar P.C., Stewart S., Rowan E.G., and Willison H.J. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124 (2001) 893-906
32. O'Hanlon G.M., Humphreys P.D., Goldman R.S., Halstead S.K., Bullens R.W., Plomp J.J., Ushkaryov Y., and Willison H.J. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126 (2003) 2497-2509
33. Pangburn M.K., and Muller-Eberhard H.J. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 2416-2420
34. Pangburn M.K., Schreiber R.D., and Muller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146 (1977) 257-270
35. Paparounas K., O'Hanlon G.M., O'Leary C.P., Rowan E.G., and Willison H.J. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 122 (1999) 807-816
36. Plomp J.J., Molenaar P.C., O'Hanlon G.M., Jacobs B.C., Veitch J., Daha M.R., Van Doorn P.A., Van der Meche F.G.A., Vincent A., Morgan B.P., and Willison H.J. Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects on motor end plates. Ann. Neurol. 45 (1999) 189-199
37. Putzu G.A., Figarella-Branger D., Bouvier-Labit C., Liprandi A., Bianco N., and Pellissier J.F. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J. Neurol. Sci. 174 (2000) 16-21
38. Rice C.E. The interchangeability of the complement components of different animal species; literature survey. Can. J. Comp Med. Vet. Sci. 14 (1950) 369-379
39. Roberts M., Willison H., Vincent A., and Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 343 (1994) 454-455
40. Roberts M., Willison H.J., Vincent A., and Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann. Neurol. 38 (1995) 111-118
41. Rohou A., Nield J., and Ushkaryov Y.A. Insecticidal toxins from black widow spider venom. Toxicon 49 (2007) 531-549
42. Sandhoff K., and Kolter T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. Lond B Biol. Sci. 358 (2003) 847-861
43. Sartucci F., Cafforio G., Borghetti D., Domenici L., Orlandi G., and Murri L. Electrophysiological evidence by single fibre electromyography of neuromuscular transmission impairment in a case of Miller Fisher syndrome. Neurol. Sci. 26 (2005) 125-128
44. Susuki K., Rasband M.N., Tohyama K., Koibuchi K., Okamoto S., Funakoshi K., Hirata K., Baba H., and Yuki N. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 27 (2007) 3956-3967
45. Uncini A., and Lugaresi A. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 22 (1999) 640-644
46. Vincent A., Lang B., and Kleopa K.A. Autoimmune channelopathies and related neurological disorders. Neuron 52 (2006) 123-138
47. Wanschitz J., Maier H., Lassmann H., Budka H., and Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 126 (2003) 2034-2042
48. Weiler J.M., Daha M.R., Austen K.F., and Fearon D.T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. U. S. A 73 (1976) 3268-3272
49. Willison H.J., and O'Hanlon G.M. The immunopathogenesis of Miller Fisher syndrome. J. Neuroimmunol. 100 (1999) 3-12
50. Willison H.J., and Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (2002) 2591-2625
51. Willison H.J., O'Hanlon G.M., Paterson G., Veitch J., Wilson G., Roberts M., Tang T., and Vincent A. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J. Clin. Invest. 97 (1996) 1155-1164
52. Wirguin I., Ifergane G., Almog Y., Lieberman D., Bersudsky M., and Herishanu Y.O. Presynaptic neuromuscular transmission block in Guillain-Barre syndrome associated with anti-GQ1b antibodies. Neuromuscul. Disord. 12 (2002) 292-293
53. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect. Dis. 1 (2001) 29-37
54. Zuo Y., Lubischer J.L., Kang H., Tian L., Mikesh M., Marks A., Scofield V.L., Maika S., Newman C., Krieg P., and Thompson W.J. Fluorescent proteins expressed in mouse transgenic lines mark subsets of glia, neurons, macrophages, and dendritic cells for vital examination. J. Neurosci. 24 (2004) 10999-11009
55. Zwirner J., Wittig A., Kremmer E., and Gotze O. A novel ELISA for the evaluation of the classical pathway of complement. J. Immunol. Methods 211 (1998) 183-190